OpenExamsFREE PRACTICE — ANY EXAM

New Mexico Pharmacist — Requirements & Free Practice

US-NM · License preparation

772 free questions · Answer explanations · No signup required

Choose what to practice

Start with an exam below. Your examination requirements depend on your application pathway. View licensing requirements

Combined practice

Choose an exam or combined practice to begin.

Licenses, application pathways and examination requirements

Each license and applicant pathway has its own requirements and exemptions. Choosing practice questions does not determine your eligibility.

Registered Pharmacist

Licence issued by the New Mexico Board of Pharmacy under the Pharmacy Act (NMSA 1978 §§ 61-11-9, 61-11-10) to practise pharmacy in New Mexico, by examination, by reciprocity, or as a provisional (expedited or military) licence by reciprocity.

Licensing authority: New Mexico Board of Pharmacy · Application information

Licensure by examination graduate of an ACPE accredited college of pharmacy
Age and fitness
Has reached the age of majority and is not addicted to the use of drugs or alcohol (NMSA 1978 § 61-11-9(A)(1)).
Application
Application filed with and approved by the Board and required fees paid (NMSA 1978 § 61-11-9(C)); current photograph (16.19.2.13 NMAC).
Education
Graduate of a college of pharmacy accredited by the ACPE (16.19.2.8(A)(1) NMAC; NMSA 1978 § 61-11-9(A)(2)).
Internship
Not less than one year of experience under the direction of a pharmacist in Board-established supervised training (NMSA 1978 § 61-11-9(A)(3)); completion of the required internship under 16.19.5 NMAC must be certified by the Board before the applicant is admitted to the examination (16.19.2.11 NMAC).
Naplex score transfer
Candidates taking the NAPLEX in participating states may transfer scores under the NABP score transfer program upon payment of the New Mexico fee, while New Mexico participates in that program; only score-transfer applicants who have passed the NAPLEX and received their score may take the MPJE (16.19.2.8(A)(4)-(5) NMAC).
Retake limits
A candidate may not take either the NAPLEX or MPJE more than four consecutive times without passing, within three years of the first attempt; waiting periods of 45 days (NAPLEX) and 30 days (MPJE) apply after a failure (16.19.2.9 NMAC).
Licensure by examination graduate of a school or college of pharmacy not accredited by the ACPE (foreign pharmacy graduate)
Age and fitness
Has reached the age of majority and is not addicted to the use of drugs or alcohol (NMSA 1978 § 61-11-9(A)(1)).
Application
Application on a form supplied by the Board (16.19.2.8(B)(1) NMAC); required fees paid (NMSA 1978 § 61-11-9(C)).
Education
Graduate of a school or college of pharmacy not accredited by the ACPE (16.19.2.8(B) NMAC; NMSA 1978 § 61-11-9(B)).
Fpgee certification program
Successful completion of the NABP FPGEE certification program (16.19.2.8(B)(3) NMAC); the FPGEE is the examination leaf, and any other element of that certification program is the applicant's condition.
Internship
Completion of the internship requirements of 16.19.5 NMAC (16.19.2.8(B)(2) NMAC), certified by the Board before admission to the examination (16.19.2.11 NMAC); applicants with work experience as a pharmacist in another country may petition the Board to accept that experience in lieu of all, part or none of the internship (16.19.2.8(C) NMAC).
Retake limits
A candidate may not take either the NAPLEX or MPJE more than four consecutive times without passing, within three years of the first attempt; waiting periods of 45 days (NAPLEX) and 30 days (MPJE) apply after a failure (16.19.2.9 NMAC).
Expedited one year provisional licence by reciprocity, converted to a regular licence after passing the NM MPJE
Application
NABP application for pharmacist license by reciprocity (license transfer program) and a pharmacist licence by reciprocity application to the Board, with the licence fee; the applicant must meet all the requirements of 16.19.3 NMAC (16.19.3.15(B)-(C) NMAC).
Licensure elsewhere
Currently licensed by examination under the laws of another US state or the District of Columbia, in good standing (16.19.3.15(C) NMAC; NMSA 1978 § 61-1-31.1(A)(2)).
Military fee exemption
Military service members, spouses, dependents and veterans are exempt from the initial licence fee and initial renewal fee on documentation of eligibility (16.19.3.15(G) NMAC; NMSA 1978 § 61-1-34(C)).
Mpje timing
The expedited licence is issued before the NM MPJE is taken; it lasts one year and is not renewed or extended as a provisional licence, and the Board renews it as a regular licence after the applicant passes the NM MPJE (16.19.3.15(B), (F) NMAC; NMSA 1978 § 61-1-31.1(B)-(C)).
Provisional licence by reciprocity for service members and spouses relocated to New Mexico on military orders
Application
Meets the requirements of 16.19.3 NMAC, completes the NABP application for pharmacist license by reciprocity and the Board's reciprocity application, provides documentation of eligibility and the military orders, and submits to the Board's authority for standards of practice, discipline and continuing education (16.19.3.16(C), (D), (F) NMAC).
Eligibility
Service member as defined in 50 USC § 3911, or spouse, who relocates residency to New Mexico because of military orders; the provisional licence lasts for the duration of those orders and is issued without taking the NM MPJE (16.19.3.16 NMAC).
Licensure elsewhere
Licence in good standing with the issuing authority and with every other authority that issued the applicant a pharmacist licence, actively used during the two years immediately preceding the relocation (16.19.3.16(A), (B), (E) NMAC).
Licensure by reciprocity pharmacist licensed by examination in another state or territory
Application
All reciprocity paperwork, including the NABP licensure transfer application, and a current photograph (16.19.3.11(A), 16.19.3.12, 16.19.3.15(B) NMAC).
Education and experience
Graduate of an approved college of pharmacy who completed required intern training, or worked one year as a licensed pharmacist in the state of licensure by examination; an applicant whose internship at the time of examination did not meet New Mexico's requirements is ineligible (16.19.3.8, 16.19.3.9(A) NMAC).
Fitness
Not addicted to alcohol, narcotic or hypnotic drugs, and no charges, convictions, fines, suspensions or revocations under 16.19.4.8 NMAC; a pending indictment or alleged violation may make the applicant ineligible (16.19.3.13(C)-(D), 16.19.3.14 NMAC).
Licensure elsewhere
Licensed as a pharmacist by examination in another US state or territory that grants reciprocal privileges to pharmacists licensed by examination in New Mexico; the licence in the state of examination must be current and in good standing (16.19.3.8, 16.19.3.9, 16.19.3.13(A) NMAC; NMSA 1978 § 61-11-10(A)).
Mpje window
The MPJE must be taken within one year after the application is received, otherwise the application is nullified; no more than four consecutive attempts without passing within three years, with a 30-day wait after a failure (16.19.3.11(B)-(C) NMAC).
Naplex timing
The NAPLEX passing score is evidence furnished with the application (16.19.3.13(B) NMAC).
Reinstatement of licensure for any reason, including revocation or expiration, where the Board requires examination
Board discretion
The Board may require an applicant for reinstatement, for any reason including revocation, to pass any combination of the NAPLEX and MPJE; which examinations, if any, apply is decided by the Board for the applicant (16.19.2.14(A)-(B) NMAC).
Expired licence
A licence that expired for failure to renew is reinstated only upon reapplication and payment of a $100 reinstatement fee and all delinquent renewal fees (NMSA 1978 § 61-11-13(A)).
Procedure
The applicant follows the same rules and procedures as if reciprocating (16.19.2.14(F) NMAC).
Reinstatement to active practice after more than two but less than six years out of pharmacy practice
Eligibility
Pharmacist not active in pharmacy practice for more than two but less than six years, including an inactive-status pharmacist returning to active status (16.19.2.14(C), 16.19.3.10(B), 16.19.4.15(B) NMAC; NMSA 1978 § 61-11-13(B)).
In lieu option
Instead of past fees, reinstatement fees and continuing education proof: at least 60 internship hours per year of inactivity and passing both the NAPLEX and the MPJE (16.19.2.14(D) NMAC; 16.19.3.10(C) NMAC).
Reciprocity licensees
A licensee originally licensed by reciprocity must also hold current licensure in the state of examination and submit a current letter of good standing from it (16.19.3.10(A), (B)(6) NMAC); applicants follow the same rules and procedures as if reciprocating (16.19.2.14(F) NMAC).
Standard option
Renewal form, past renewal and reinstatement fees, proof of continuing education for each inactive renewal period, proof of at least 60 internship hours per year of inactivity, and the MPJE (16.19.2.14(C) NMAC; 16.19.3.10(B) NMAC).
Reinstatement to active practice after six or more years out of pharmacy practice
Eligibility
Pharmacist not active in pharmacy practice for six years or more (16.19.2.14(E), 16.19.3.10(D) NMAC).
Internship
At least 60 internship hours for each year of inactivity (16.19.2.14(E)(1), 16.19.3.10(D)(1) NMAC).
Reciprocity licensees
A licensee originally licensed by reciprocity must hold current licensure in the state of examination (16.19.3.10(A) NMAC); applicants follow the same rules and procedures as if reciprocating (16.19.2.14(F) NMAC).
Biennial renewal of a current pharmacist licence (active or inactive status)
No examination is required for this applicant pathway.
Continuing education
Proof of completed continuing education (NMSA 1978 § 61-11-13(D); 16.19.4.10 NMAC).
Renewal
Application for renewal on Board forms before the last day of the birth month, indicating active or inactive status, with the renewal fee (NMSA 1978 § 61-11-13(A), (C)).
Return to active
An inactive pharmacist out of practice for two or more years who seeks active status reinstates through the reinstatement routes (16.19.2.14 NMAC; 16.19.4.15(B) NMAC).

Official no-examination sources

Effective from 2020-07-01.

Pharmacist Clinician

Certification and registration of a pharmacist as a pharmacist clinician under the Pharmacist Prescriptive Authority Act.

Licensing authority: New Mexico Board of Pharmacy · Application information

Initial certification and registration as a pharmacist clinician
No examination is required for this applicant pathway.
Application
Board application forms and non-returnable fee (16.19.4.17(B)(2) NMAC).
Controlled substances
Applicants requesting Schedule II or III prescribing registration must be trained in responsible opioid prescribing practices (16.19.4.17(B)(3)(d) NMAC).
Pharmacist licence
Must be a pharmacist licensed by the Board (16.19.4.17(B)(1) NMAC; NMSA 1978 § 61-11B-2).
Prescriptive authority
Exercising prescriptive authority requires a current protocol with a supervising physician registered with the New Mexico Medical Board (16.19.4.17(D) NMAC; NMSA 1978 § 61-11B-3).
Training
Proof of a 60-hour Board-approved physical assessment course followed by a 150-hour, 300-patient-contact preceptorship supervised by a physician or other practitioner with prescriptive authority, with a patient encounter log; encounters initiated and completed within two years of the application (16.19.4.17(B)(3)(a)-(c) NMAC).

Official no-examination sources

Effective from 2024-05-07.

Biennial renewal of pharmacist clinician registration
No examination is required for this applicant pathway.
Renewal
Renewal application submitted before licence expiration with 20 contact hours of additional continuing education (at least 10 live), opioid-prescribing CE for Schedule II/III prescribers, the current collaborative-practice protocol and supervising-physician registration where prescriptive authority is sought, and other information the Board requests (16.19.4.17(C) NMAC).

Official no-examination sources

Effective from 2024-05-07.

Foreign Pharmacy Graduate Equivalency Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
200 questions
Time limit
4.5 hours examination time; 5.5 hours total seat time
Passing score
Scaled score of 75
Examination outline
  • Foundational Biomedical Sciences (12%)
    • Anatomy and physiology
    • Biochemistry
    • Medical microbiology
    • Immunology
    • Pathophysiological bases of diseases
  • Pharmaceutical Sciences (31%)
    • Pharmaceutical calculations (eg, dose adjustments, delivery, ionization, ionic strength, isotonicity, ratio/percentage strength, osmolarity)
    • Medicinal chemistry
    • Medicinal chemistry: Physicochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
    • Medicinal chemistry: Pathways of drug metabolism
    • Medicinal chemistry: Chemical bases for drug action, including bioorganic chemistry, structure-activity relationships, and fundamental pharmacophores related to drug-receptor interactions
    • Medicinal chemistry: Applicability to making drug therapy decisions
    • Pharmacology and toxicology
    • Pharmacology and toxicology: Pharmacodynamics, including drug-receptor interactions, agonists, antagonists, inverse agonists, and dose-response curves
    • Pharmacology and toxicology: Mechanisms of action of drugs, including biologics
    • Pharmacology and toxicology: Adverse effects and side effects of drugs
    • Pharmacology and toxicology: Mechanisms of drug interactions, including drug-drug, drug-disease, drug-food, drug-allergy, and drug-laboratory interactions
    • Pharmacology and toxicology: Mechanisms of acute and chronic toxic effects of xenobiotics, including drug and chemical overdose or exposure and antidotes
    • Pharmaceutics and biopharmaceutics
    • Pharmaceutics and biopharmaceutics: Dosage form development and drug delivery systems such as immediate release, sustained release, and controlled release
    • Pharmaceutics and biopharmaceutics: Disintegration and dissolution of solid oral dosage forms
    • Pharmaceutics and biopharmaceutics: Physicochemical properties of drugs, excipients, solutions, and dosage forms
    • Pharmaceutics and biopharmaceutics: Physical stability, chemical stability, and shelf-lives, including zero-, first-, second-, and pseudo-order reactions
    • Pharmaceutics and biopharmaceutics: Interactions between drug formulation and biological effects
    • Pharmaceutics and biopharmaceutics: Drug product manufacturing, including methods, processing, and quality assurance
    • Pharmacokinetics
    • Pharmacokinetics: Determining rates of absorption, distribution, metabolism, and excretion (ADME) of drugs
    • Pharmacokinetics: Factors affecting rates of ADME, including age, sex, genetics, diet, disease, and drug interactions
    • Pharmacokinetics: Biological half-lives of drugs and related dosing
    • Pharmacokinetics: Compartment models (one-, two-, and non-)
    • Pharmacokinetics: Linear and nonlinear pharmacokinetics
    • Pharmacokinetics: Principles of bioavailability, bioequivalence, and biosimilars
    • Pharmacogenomics (eg, population-based genetic influences on drug metabolism and efficacy, genetic testing, tumor genotyping, pharmacogenetic screening)
    • Extemporaneous compounding (eg, United States Pharmacopeia (USP) standards including Chapters <795>, <797>, and <800>; dosage form preparation calculations; techniques used to prepare and dispense sterile and nonsterile preparations)
  • Social, Behavioral, and Administrative Sciences (20%)
    • Pharmacy law and ethics
    • Pharmacy law and ethics: Laws and regulations governing pharmacy
    • Pharmacy law and ethics: Regulatory, oversight, and professional organizations
    • Pharmacy law and ethics: Principles and application of biomedical ethics
    • Health care systems
    • Health care systems: Organization, regulation, and financing of health care delivery in the United States
    • Health care systems: Factors that influence delivery and use of health care (eg, social, political, economic, and technological)
    • Pharmacoeconomics (eg, analysis, interpretation, application, humanistic outcomes)
    • Population-based care, pharmacoepidemiology, and public health
    • Population-based care, pharmacoepidemiology, and public health: Data sources and analytic tools
    • Population-based care, pharmacoepidemiology, and public health: Application of epidemiological study design
    • Population-based care, pharmacoepidemiology, and public health: Health promotion, disease prevention, and infection control
    • Population-based care, pharmacoepidemiology, and public health: Continuous quality improvement
    • Population-based care, pharmacoepidemiology, and public health: Social determinants and drivers of health
    • Practice management
    • Practice management: Financial management and budgeting
    • Practice management: Personnel management
    • Practice management: Business and strategic planning
    • Practice management: Risk management
    • Practice management: Procurement and inventory control
    • Professional communication
    • Professional communication: Verbal, nonverbal, written, and technology-based communication with patients, caregivers, providers, and stakeholders
    • Professional communication: Health literacy
    • Biostatistics and research methods (eg, study design, statistical tests, data collection instruments, research ethics)
    • Social and behavioral aspects of practice
    • Social and behavioral aspects of practice: Patient behavior including health-, illness-, and sick-role
    • Social and behavioral aspects of practice: Principles of behavior modification
    • Social and behavioral aspects of practice: Patient adherence
    • Social and behavioral aspects of practice: Cultural awareness
  • Pharmacy Practice and Clinical Sciences (37%)
    • Clinical pathophysiology as it applies to treatment of disease processes
    • Data collection (eg, patient history, physical assessments, laboratory values, point-of-care testing)
    • Data assessment (eg, clinical calculations, interpretation of data, diagnosing)
    • Patient-care decision making, therapy recommendations, and education (eg, plan, implement, monitor, follow-up)
    • Patient safety (eg, drug interactions, toxicity, drug-induced disease, drug use disorders)
    • Disease prevention (eg, screenings, immunization, non-pharmacological therapies, lifestyle modifications)
    • Personalized medicine (eg, pharmacokinetics, pharmacogenetics)
    • Evidence-based practice
    • Evidence-based practice: Practice guidelines
    • Evidence-based practice: Drug information and evaluation
    • Evidence-based practice: Information source reliability
    • Evidence-based practice: Clinical trial evaluation
    • Self-care, including using natural products
Examination sources

North American Pharmacist Licensure Examination

Provider
National Association of Boards of Pharmacy
Format
Computerized fixed form
Exam questions
225 questions
Time limit
6 hours
Passing score
Pass or Fail
Examination outline
  • Foundational Knowledge for Pharmacy Practice (25%)
    • Pharmaceutical science principles and concepts
    • Pharmaceutical science principles and concepts: Pharmacology
    • Pharmaceutical science principles and concepts: Pharmacokinetics, pharmacodynamics, or pharmacogenomics
    • Pharmaceutical science principles and concepts: Pharmaceutics
    • Pharmaceutical compounding
    • Pharmaceutical compounding: Nonsterile preparations
    • Pharmaceutical compounding: Sterile preparations
    • Pharmaceutical calculations
    • Pharmaceutical calculations: Patient parameters or laboratory measures
    • Pharmaceutical calculations: Quantities of drugs to be dispensed or administered
    • Pharmaceutical calculations: Rates of administration
    • Pharmaceutical calculations: Dose conversions
    • Pharmaceutical calculations: Drug concentrations, ratio strengths, osmolarity, or osmolality
    • Pharmaceutical calculations: Quantities of drugs or ingredients to be compounded
    • Pharmaceutical calculations: Nutritional needs and the content of nutrient sources
    • Pharmaceutical calculations: Biostatistical, epidemiological, or pharmacoeconomic measures
    • Pharmaceutical calculations: Pharmacokinetic parameters
    • Drug development processes (eg, clinical trial phases, emergency use authorizations)
    • Research design principles and biostatistics (eg, blinding, randomization, biases, statistical tests and outcomes, ethics)
    • Retrieval, assessment, and interpretation of primary, secondary, and tertiary resources
  • Medication Use Process (Prescribing, Transcribing and Documenting, Dispensing, Administering, and Monitoring) (25%)
    • Prescriptions and medication order interpretation
    • Prescriptions and medication order interpretation: Drug names and therapeutic classes
    • Prescriptions and medication order interpretation: Indications, usage, and dosing regimens
    • Prescriptions and medication order interpretation: Available dosage forms
    • Prescriptions and medication order interpretation: Prescription regulations (eg, boxed warnings, risk evaluation and mitigation strategies)
    • Prescriptions and medication order interpretation: Safety and effectiveness (eg, laboratory parameters, vital signs)
    • Therapeutic substitutions (eg, formulary restrictions, therapeutic alternatives, shortages, biosimilars)
    • Immunization services and documentation
    • Immunization services and documentation: Indications and scheduling
    • Immunization services and documentation: Contraindications and precautions
    • Immunization services and documentation: Storage and handling
    • Immunization services and documentation: Administration (eg, techniques, preparation, routes)
    • Immunization services and documentation: Adverse reactions
    • Medication handling, storage, stability, and disposal (eg, hazardous and nonhazardous drugs, controlled substances, parenteral medications, sharps handling, temperature control)
  • Person-Centered Assessment and Treatment Planning (40%)
    • Medication history, allergy history, and reconciliation
    • Health histories, screenings, and assessments
    • Patient health conditions, including special populations and medication-related factors
    • Patient health conditions, including special populations and medication-related factors: Signs, symptoms, and findings of medical conditions, etiology of diseases, or pathophysiology
    • Patient health conditions, including special populations and medication-related factors: Appropriateness of therapy (eg, medications, immunizations, non-drug therapy, dosing, contraindications, warnings, evidence-based decision making)
    • Patient health conditions, including special populations and medication-related factors: Interactions (eg, drug-drug, drug-condition, drug-food, drug-allergy, drug-laboratory)
    • Patient health conditions, including special populations and medication-related factors: Errors and omissions (eg, dosing, duplication, additional therapy needed, unnecessary therapy)
    • Patient health conditions, including special populations and medication-related factors: Adverse drug reactions
    • Patient health conditions, including special populations and medication-related factors: Toxicologic exposures and overdoses
    • Patient health conditions, including special populations and medication-related factors: Adherence
    • Therapeutic monitoring, plan development, evaluation, and modifications
    • Therapeutic monitoring, plan development, evaluation, and modifications: Therapeutic goals, clinical endpoints, and follow-up
    • Therapeutic monitoring, plan development, evaluation, and modifications: Safety
    • Therapeutic monitoring, plan development, evaluation, and modifications: Effectiveness
    • Patient education
    • Patient education: Lifestyle modifications and health maintenance
    • Patient education: Medication use, storage, and disposal
    • Patient education: Disease state management
    • Over-the-counter medications and dietary supplements
    • Devices to administer medications and self-monitoring tests
  • Professional Practice (5%)
    • Adverse drug event reporting and medication error reporting (eg, MedWatch, VAERS)
    • Public health initiatives and risk-prevention programs (eg, tobacco and nicotine cessation, antimicrobial stewardship, health screenings, opioid stewardship)
    • Social determinants and drivers of health
    • Ethical considerations (eg, informed consent, ethical principles, professional conduct and responsibility, patient confidentiality)
  • Pharmacy Management and Leadership (5%)
    • Pharmacy operations (eg, operational planning, risk management, regulations and regulatory bodies, technology applications and informatics, error-prevention strategies, medication safety)
    • Inventory and supply management (eg, drug recalls, drug shortages)
    • Quality improvement activities (eg, medication use evaluation, root-cause analysis, continuous quality improvement)
    • Mentorship and preceptorship (eg, providing and receiving feedback, delegation of work activities, preceptor roles)
Examination sources

Multistate Pharmacy Jurisprudence Examination

Provider
National Association of Boards of Pharmacy (NABP)
Format
Computer-based adaptive exam of selected-response questions (multiple choice and multiple response)
Exam questions
120 questions, of which 100 are scored and 20 are unscored pretest questions
Time limit
2.5 hours (3-hour total appointment)
Passing score
Pass/fail; candidates must achieve a passing score as set by NABP (16.19.2.8(A)(3) NMAC)
Exam fee
$100 eligibility application fee per jurisdiction plus $170 examination fee
Examination outline
  • Area 1 — Licensure/Personnel (22%)
    • Responsibilities of the pharmacist and non-pharmacist personnel: qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for pharmacists-in-charge (or equivalent) and pharmacists; qualifications, scope of duties, limitations, and restrictions of duties, or conditions to practice for non-pharmacist personnel
    • Licensures, registrations, and certifications for pharmacists or non-pharmacist personnel: qualifications, examinations, internships, maintaining pharmacist competency, and renewals of licensures, registrations, or certifications; classifications and processes of disciplinary actions; reporting to and participating in programs addressing the inability to practice with reasonable skill and safety
  • Area 2 — Pharmacist Practice (33%)
    • Requirements for issuing prescriptions/drug orders: requirements for drug uses, limitations, or restrictions; scope of authority, scope of practice, limitations or restrictions of practice, and valid registration of practitioners who are authorized to prescribe, dispense, or administer drugs; requirements for issuing non-controlled prescriptions/drug orders; requirements for issuing controlled prescriptions/drug orders; authority limitations of practitioners' ability to authorize refills
    • Conditions under which the pharmacist or non-pharmacist personnel participates in the administration of drugs in the management of patients' therapy
    • Requirements regarding counseling: counseling or offering to counsel; documenting counseling or documenting offering to counsel
    • Returning or reusing drugs
    • Regulations and agencies regarding pharmacy practice: requirements for promoting quality and safety of public health; protecting patient and health record confidentiality
  • Area 3 — Dispensing Requirements (24%)
    • Responsibilities for determining whether prescriptions/drug orders are issued for a legitimate medical purpose, and within all applicable restrictions
    • Transferring prescription/drug order information between pharmacies by authorized personnel
    • Prospective drug utilization reviews: requirements for reporting to PMP and accessing PMP data
    • Exceptions to dispensing or refilling prescriptions/drug orders
    • Labeling of dispensed drugs
    • Packaging of dispensed drugs
    • Drug product conditions prohibiting dispensing
    • Requirements for the distribution and/or dispensing of non-prescription pharmaceutical products, including controlled substances and hazardous drugs: dispensing or administration; labeling of non-prescription drugs and devices; packaging and repackaging of non-prescription drugs and behind-the-counter products; dispensing-restricted, non-prescription drugs
  • Area 4 — Pharmacy Operations (21%)
    • Ordering, acquisition, and distribution of drugs, including maintenance and content of such records: ordering and acquisition, including the maintenance and content of such records; distribution, including the maintenance and content of such records
    • Recordkeeping in compliance with legal requirements, including content, inventory, maintenance, storage, handling, and reporting: non-dispensing requirements for operations of pharmacies or practice settings; possession, storage, and handling of non-hazardous drugs; training, possession, handling, storage, and disposal of hazardous drugs; allowing non-pharmacist personnel access to drugs; requirements for conducting controlled substance inventories
    • Delivery of drugs
    • Conditions for permitted or mandated product selection
    • Compounding sterile, nonsterile, hazardous, and non-hazardous preparations
    • Centralized prescription processing or central-fill pharmacy dispensing
    • Requirements for the registration, licensure, certification, or permitting of a practice setting or business entity: requirements for registration, license, certification, or permitting of a practice setting; requirements for the renewal or reinstatement of a license, registration, certificate, or permit of a practice setting; requirements for an inspection of a licensed, registered, certified, or permitted practice setting; classifications and processes of disciplinary actions that may be taken against a registered, licensed, certified, or permitted practice setting
Examination sources